OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety
Cheng Jiang, Jiancheng Qian, Xin Jiang, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Cheng Jiang, Jiancheng Qian, Xin Jiang, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Showing 10 citing articles:
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Yiming Qi, Jing Li, Sisi Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Yiming Qi, Jing Li, Sisi Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Management options for excessive daytime sleepiness in patients with obstructive sleep apnea
Maria R. Bonsignore, Francesco Fanfulla, Pietro Ingrao, et al.
Expert Review of Respiratory Medicine (2025)
Closed Access
Maria R. Bonsignore, Francesco Fanfulla, Pietro Ingrao, et al.
Expert Review of Respiratory Medicine (2025)
Closed Access
Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
Chuang Yang, Baoguo Deng, Qiang Wen, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Chuang Yang, Baoguo Deng, Qiang Wen, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
Jiancheng Qian, Shuohan Zhang, Cheng Jiang
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Jiancheng Qian, Shuohan Zhang, Cheng Jiang
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime
Cheng Jiang, Xiaoxiao Zheng, Ping Li, et al.
Therapeutic Advances in Drug Safety (2024) Vol. 15
Open Access | Times Cited: 1
Cheng Jiang, Xiaoxiao Zheng, Ping Li, et al.
Therapeutic Advances in Drug Safety (2024) Vol. 15
Open Access | Times Cited: 1
Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database
Xiaochen Wan, Shuohan Zhang, Cheng Jiang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access | Times Cited: 1
Xiaochen Wan, Shuohan Zhang, Cheng Jiang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access | Times Cited: 1
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
Jialing Hu, Jing-Ying Wu, Shan Xu, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Jialing Hu, Jing-Ying Wu, Shan Xu, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Aripiprazole/Diazepam/Fluvoxamine/Pitolisant
Reactions Weekly (2024) Vol. 2005, Iss. 1, pp. 114-114
Closed Access
Reactions Weekly (2024) Vol. 2005, Iss. 1, pp. 114-114
Closed Access
Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA adverse event reporting system database
Shuangshuang Wu, Yiming Qi, Cheng Jiang, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
Shuangshuang Wu, Yiming Qi, Cheng Jiang, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
